Effectiveness and Safety for Re-treatment With Brentuximab-Vedotin (BV) in Patients With Relapsed/Refractory (R/R) CD30+ Malignancies: a Retrospective Medical Chart Review Study in Spain

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Brentuximab vedotin (Primary)
Indications Hodgkin's disease; Mycosis fungoides; Non-Hodgkin's lymphoma; Primary cutaneous anaplastic large cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms BELIEVE
Sponsors Takeda

08 Jul 2024 Status changed from active, no longer recruiting to completed.
16 Aug 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2024.
16 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com